National Comprehensive Cancer Network®

NCCN 2026 Annual Congress: Hematologic Malignancies™
Friday, September 18 – Saturday, September 19, 2026
New York, NY | In-Person & Virtual

CONGRESS AGENDA

On-Demand Sessions

Individualizing Treatment for Patients with Waldenström Macroglobulinemia**
Shayna Sarosiek, MD, *Dana-Farber Cancer Institute | Harvard Medical School*

Erdheim-Chester Disease: The Role of Molecular Testing in Treatment Planning
Gaurav Goyal, MD, *O'Neal Comprehensive Cancer Center at UAB*

The Evolving Treatment Landscape in Myeloproliferative Neoplasms**
Andrew T. Kuykendall, MD, *Moffitt Cancer Center*

Advances in Systemic Mastocytosis**
Lindsay Rein, MD, *Duke Cancer Institute*

Treating Adult Patients with Burkitt Lymphoma**
Sunita D. Nasta, MD, *Abramson Cancer Center at the University of Pennsylvania*

Psychosocial Support for Adolescent and Young Adult Patients with Hematologic Malignancies
Jeanelle Folbrecht, PhD, *City of Hope National Medical Center*

Friday, September 18, 2026

All times are listed as Eastern Daylight Time (UTC/GMT -4).

12:00 – 1:00 PM	**Registration and Exhibits**
12:20 – 12:50 PM	**Non-CE Product Theater*: A New Therapeutic Option for ET** *Presented by PharmaEssentia*
1:00 – 1:05 PM	**Opening Remarks** | Andrew D. Zelenetz, MD, PhD, *Memorial Sloan Kettering Cancer Center*
1:05 – 1:35 PM	**Transforming the Management of Acute Lymphoblastic Leukemia**** Benjamin Tomlinson, MD, *Case Comprehensive Cancer Center/ University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute*
1:35 – 2:05 PM	**Oral Targeted Therapies in Relapsed/Refractory Acute Myeloid Leukemia**** Kateryna Fedorov, MD, *Vanderbilt-Ingram Cancer Center*
2:05 – 2:35 PM	**Chronic Myeloid Leukemia: De-Escalation of TKI Therapy**** Vivian G. Oehler, MD, *Fred Hutchinson Cancer Center*
2:35 – 3:05 PM	**Managing Toxicities of Outpatient Oral Therapies for Chronic Myeloid Leukemia**** Jenna Moran, MSN, FNP-BC, *Mass General Cancer Institute*
3:05 – 3:25 PM	**Break and Exhibits**
3:10 – 3:40 PM	**Non-CE Product Theater*: 1 DLBCL: Primary and Latest PFS Data** *Presented by Genentech*
3:25 – 3:55 PM	**The Role of Clonal Hematopoiesis in Hematologic Malignancies**** Amy E. DeZern, MD, MHS, *Johns Hopkins Kimmel Cancer Center*
3:55 – 5:25 PM	**Evolving Treatment Strategies in Newly Diagnosed & Relapsed/Refractory Multiple Myeloma**** Natalie S. Callander, MD, *University of Wisconsin Carbone Cancer Center* Beth Faiman, PhD, MSN, APRN-BC, TCTCN, AOCN, FAAN, FAPO, *Cleveland Clinic Taussig Cancer Institute* Malin Hultcrantz, MD, PhD, *Memorial Sloan Kettering Cancer Center* Shaji K. Kumar, MD, *Mayo Clinic Comprehensive Cancer Center*
5:25 – 5:30 PM	**Closing Remarks** | Andrew D. Zelenetz, MD, PhD, *Memorial Sloan Kettering Cancer Center*
5:30 – 7:00 PM	**Welcome Reception and Exhibits** (*In-Person Only Event*)

NCCN.org/hem

Agenda is subject to change.
**Not CE-certified.*
***Offers pharmacotherapeutic contact hours for nurses.*

Non-CE Product Theaters: *The information and views expressed in these presentations are solely that of the presenters and do not necessarily reflect the position and policies of NCCN. NCCN makes no warranties of any kind whatsoever regarding their content, use, or application and disclaims any responsibility for their application or use in any way.*

National Comprehensive Cancer Network®

NCCN 2026 Annual Congress: Hematologic Malignancies™
Friday, September 18 – Saturday, September 19, 2026
New York, NY | In-Person & Virtual

CONGRESS AGENDA

SATURDAY, SEPTEMBER 19, 2026

All times are listed as Eastern Daylight Time (UTC/GMT -4).

7:00 – 8:00 AM	**Registration, Breakfast, and Exhibits**
7:20 – 7:50 AM	**Non-CE Product Theater*: Fixed-Duration Pirtobrutinib + Venetoclax–Rituximab (VenR) vs VenR for R/R CLL/SLL (BRUIN CLL-322)** *Presented by Eli Lilly and Company*
8:00 – 8:05 AM	**Opening Remarks** | Andrew D. Zelenetz, MD, PhD, *Memorial Sloan Kettering Cancer Center*
8:05 – 9:05 AM	**Outpatient Administration of Bispecific Antibodies and CAR T-Cell Therapies**** Marcos J. de Lima, MD, *The Ohio State University Comprehensive Cancer Center – James Cancer Hospital and Solove Research Institute* Jacqueline Dela Peña, PharmD, BCOP, *Memorial Sloan Kettering Cancer Center* Tara M. Graff, DO, MS, *Mission Cancer and Blood, University of Iowa Health Care* Kathy Mooney, MSN, RN, ACNS-BC, TCTCN, OCN, *Johns Hopkins Kimmel Cancer Center*
9:05 – 10:20 AM	**Managing Toxicities of Bispecific Antibodies and CAR T-Cell Therapies in the Outpatient Setting**** Carissa Laudati, MSN, FNP-BC, OCN, *Memorial Sloan Kettering Cancer Center* Olalekan Oluwole, MBBS, MPH, *Vanderbilt-Ingram Cancer Center* Salyka M. Sengsayadeth, MD, *Vanderbilt-Ingram Cancer Center* Katie Tobon, PharmD, BCOP, *Moffitt Cancer Center*
10:20 – 10:40 AM	**Break and Exhibits**
10:25 – 10:55 AM	**Non-CE Product Theater*: MIMRYLO (rusfertide): A New Era in Polycythemia Vera (PV)** *Presented by Takeda Pharmaceuticals*
10:40 – 11:10 AM	**Working Toward Unified Classification of Hematolymphoid Malignancies** Pallavi Kanwar Galera, MD, *Memorial Sloan Kettering Cancer Center*
11:10 – 11:40 AM	**Current and Emerging Treatment Options for Peripheral T-Cell Lymphomas**** Stefan K. Barta, MD, MS, *Abramson Cancer Center at the University of Pennsylvania*
11:40 AM – 12:40 PM	**Lunch and Exhibits**
12:00 – 12:30 PM	**Non-CE Product Theater*: First-Line Treatment Option for Lower-Risk MDS COMMANDS Trial Overview** *Presented by Bristol Myers Squibb*
12:40 – 1:25 PM	**Chronic Lymphocytic Leukemia: Navigating First-Line and MRD-Guided Treatment Options**** Matthew J. Cortese, MD, MPH, *Roswell Park Comprehensive Cancer Center*
1:25 – 1:55 PM	**Optimizing Treatment for Relapsed/Refractory Follicular Lymphoma**** Peter A. Riedell, MD, *The UChicago Medicine Comprehensive Cancer Center*
1:55 – 2:10 PM	**Break**
2:10 – 2:40 PM	**Evolving Strategies in Relapsed/Refractory Diffuse Large B-Cell Lymphoma**** Jeremy S. Abramson, MD, MMSc, *Mass General Brigham Cancer Institute*
2:40 – 3:10 PM	**Update on the Diagnosis and Management of Marginal Zone Lymphomas**** C. Babis Andreadis, MD, MSCE, *UCSF Helen Diller Family Comprehensive Cancer Center*
3:10 – 3:55 PM	**Collaborative Strategies for Optimizing Small-Volume Drug Delivery**** MiKaela M. Olsen, DNP, APRN-CNS, AOCNS, FAAN, *Johns Hopkins Kimmel Cancer Center* Grace H. Pak, PharmD, MHA, BCPS, *Johns Hopkins Kimmel Cancer Center*
3:55 – 4:00 PM	**Closing Remarks** | Andrew D. Zelenetz, MD, PhD, *Memorial Sloan Kettering Cancer Center*

NCCN.org/hem

Agenda is subject to change.
**Not CE-certified.*
***Offers pharmacotherapeutic contact hours for nurses.*

Non-CE Product Theaters: *The information and views expressed in these presentations are solely that of the presenters and do not necessarily reflect the position and policies of NCCN. NCCN makes no warranties of any kind whatsoever regarding their content, use, or application and disclaims any responsibility for their application or use in any way.*